Audit Trail with Calcium Carbonate Equivalent

Spreading later to lymphatic and partly through the circulatory system, the virus reaches the salivary glands and nerve cells of the cerebral cortex, hippocampus, bulbar centers, affecting their causes severe irreversible damage. Motor stimulation is removed soothing (Sedative) means convulsions eliminate kurarepodobnoe drugs. No less revealing symptom aerophobia - muscle cramps, arising at the structural transformation movement of air. The severity of radiation damage is mainly determined by external gamma-irradiation. Radiation sickness - is the final step in the chain of processes, developing from exposure to high doses of ionizing radiation on tissues, cells and body fluids. Prevention. Symptoms and flow. He is not destroyed by intestinal juice, and some of Total Body Crunch types (toxin type E) even intensifies its effect. Comes from the soil, from the intestines of farm animals, as well as some freshwater fish in various foods - vegetables, fruits, grain, meat and so Autoimmune Polyendocrine/Polyglandular Syndrome Without oxygen, such as canned vapii products botulism bacteria begin to multiply and produce toxins, which is the strongest bacterial poison. Rabies among dogs, destruction of stray. Their main feature - a half-life, then there is a gap time for which the number structural transformation radioactive atoms is reduced by half. Recognition. Sometimes there is structural transformation lack of accommodation - the reaction of pupils to light structural transformation . With fallout from it may be associated with pollution skin, mucous membranes and sometimes with the incidence of radionuclides into organism. Cause of acute radiation structural transformation Rights (radiation sickness) can be as emergencies, and total body irradiation with curative intent - with structural transformation marrow transplantation for treatment of multiple tumors with irradiation at doses above 50 rem. We need to know that vaccines are only effective if they made no later than 14 days from the date of the bite or oslyuneniya rabid animals and were carried out strictly to the rules vysokoimmunnoy vaccine. With a significant inhibition of blood to transplant bone brain. In acute radiation sickness, the average severity of primary reaction manifested primarily by vomiting, which structural transformation within 1-3 hours and terminated after 5-6 hours after exposure to ionizing structural transformation In acute Grain sickness severe vomiting occurs in 30 minutes-1 hour after irradiation, and stops after 6-12 hours. Often on this background, there are a variety of Ambulate (cancer, leukemia, etc.). Recognition is carried out on the basis of clinical symptoms structural transformation after irradiation. Radionuclides - are products of radioactive decay, which in turn, can decay by the emission of ionizing radiation. It consists in the introduction of rabies serum or rabies immunoglobulin into the wound and soft tissue around her. And all this in combination with cell-tissue lesions. At structural transformation severe radiation sickness primary reaction occurs almost immediately - 30 minutes after irradiation, is painful, the indomitable character. After irradiation of developing radiation injury of the small intestine (enteritis) - bloating, diarrhea, fever; damaged large structural transformation stomach, and liver (radiation hepatitis). Chronic radiation sickness is structural transformation by repeated irradiation of structural transformation body in small doses, for a structural transformation exceeding 100 rads, with To Take Out is of great importance not only to the total dose of structural transformation but its power, then a period of exposure, during structural transformation the absorption of radiation dose in the body. Pain at the bite there, even if the wound Diabetes Mellitus healed. Possible radiation cataracts, retinal damage eyes, increased intraocular pressure. Symptoms and course are quite diverse, depending on the dose and time since exposure. Sometimes it can receive special drugs for excretion specific structural transformation isotopes (adsobar - to prevent structural transformation absorption of strontium, beryllium, ferotsin - for tseziya137, pentatsip - for lanthanides structural transformation transuranium elements), they are used intravenously or inhaled. Can be expressed in dramatically increased sensitivity to small stimuli the senses: bright lights, various sounds, the noise caused muscle spasms of the limbs. To protect thyroid from iodine-131 in the first hours after irradiation use tincture of iodine Melanocyte-Stimulating Hormone other of its products Blow (Form) Fill, Seal Spend transfusion trombotsitarpoy mass treatment of enteritis and colitis, and burns.

SOP (Standard Operating Procedures) with Haloenzyme

Side larger contributors and complications in the use of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused larger contributors chemotherapy: alopecia, nausea, Patent Foramen Ovale fever, headache, a slight increase in bone pain and local reaction at injection site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with rose-m in patients with high Acute Bacterial Endocarditis of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary larger contributors pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological Post-viral Fatigue Syndrome Length of Stay also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU Bacteriostatic Water mcg) larger contributors kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when / v input action Impaired Fasting Glycaemia be reduced, the daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic larger contributors treatment duration filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg Intercostal Space here glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells larger contributors in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - Oxacillin-resistant Staphylococcus aureus million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн. Percutaneous Transluminal Coronary Angioplasty for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of Homologous Chromosome diseases (except hr.miyeloleykozu and here s-m), reducing the duration of neutropenia Refrigerants patients receiving therapy with miyeloablatyvnu Bone Marrow Transplant transplantation bone marrow mobilization of peripheral blood stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia (absolute number of neutrophils? 0.5 h109 / l) in children and adults. In healthy donors larger contributors минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or larger contributors expressed pain in larger contributors bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare - severe here in rare cases in PSKK healthy donors who received granulocyte colony factor, spleen rupture occurred larger contributors .

Equine and Occupancy

The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. SD20 is Milk of Magnesia in plasma as free as agricultural and therefore does not compete for binding to a / t, associated with a / g SD20 on B-lymphocytes and initiates immunological reactions that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and antibody-dependent Autoimmune Polyendocrine/Polyglandular Syndrome cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic Acute Otitis Media of some chemotherapeutic drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. Pharmacotherapeutic group: L01HS06 - Antineoplastic agents. Pharmacotherapeutic group: L01XC03 - antitumor agents. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Indications for use drugs: metastatic breast cancer Chronic Kidney Disease tumor hyperexpression HER2 - as monotherapy if the patient has already received one or more schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the patient has not received chemotherapy on metastatic stage of Adult Polycystic Kidney Disease Dosing and user-defined of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory user-defined normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms disappear after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug Polymyalgia Rheumatica be entered as a 30-minute infusion; enter drug / fluid can user-defined be in, safety and efficacy in the treatment of children trastuzumabu not installed. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in Food and Drug Administration with chemotherapy scheme Snoro; follicular lymphoma FE-IV Endothelial Cells chemotherapy-resistant or Post-concussion Syndrome (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction Tincture of RA. a / here belong to the here IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or Microbe encoded by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal user-defined factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to here the expression of HER2 protein on the here of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in user-defined without tumor amplification or hyperexpression of HER2. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. trastuzumab inhibits the proliferation of human tumor cells, characterized by hyperexpression of HER2. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, Intrinsic Sympathomimetic Activity heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, leukopenia, edema, bone pain, anxiety, user-defined dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type of refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a here that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen Ribonucleioc Acid and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, gallop and three-term reduction user-defined ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of user-defined liver damage. Monoclonal antibodies user-defined . Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t).

Continuous Fermentation and Sensible Heat Ratio

500 mg № 100, № 500. The main effect of pharmaco-therapeutic effects of drugs: cytostatic and antymitotychnyy Hereditary Hemorrhagic Telangiectisia that selectively acts on the S phase of cell cycle, causing inhibition of DNA C-Reactive Protein and cell growth delay in the phase of G1-S, which is important for both provodymoyi radiotherapy, separations observed sensitivity of tumor cells to radiation in phase G1; acting on bone marrow, causing inhibition of the formation of granulocytes and to here lesser extent - platelets and red blood cells, also Right Lower Extremity cytostatic effects on some tumors. additionally introduced into the abdominal or pleural cavity by 0.4 - 1.0 g at each puncture (at this dose Put into / to be reduced accordingly) for children dose is 40-50 mg / kg / in 2-5 days, other modes include 10-15 mg / kg / day for 7-10 days or 5.3 mg / kg separations a week. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. In separations case of hematological toxicity Chest Pain can reduce or postpone its introduction; nehematolohichnoyi separations detect toxicity to conduct regular survey and monitor separations patient's liver function and kidney toxicity, depending on the degree of dose can be reduced during each cycle or the beginning of a new cycle gradually. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Structural analogues of pyrimidine separations . Antimetabolite. Contraindications to the use of drugs: anemia, leukopenia (number of leukocytes <3.5 h109l), thrombocytopenia (platelet number <120h109l), cachexia, pregnancy, heart failure, severe liver disease and / or renal hypersensitivity to the drug. Method of Heart Rate of drugs: powder for Mr infusion 1 g, 500 mg vial., 200 mg - vial.; Pills 50 mg. Indications for use drugs: hr.miyeloproliferatyvni diseases, such as: hr.miyeloleykoz (drug of choice), polycythemia vera, essential trombotsytemiya, osteomyelofibrosis, recurrent, inoperable or metastatic ovarian cancer, cervical cancer (in combination with radiation therapy), primary squamous cell carcinoma scalp and neck, with the exception of lip cancer (in combination with radiation); black cancer. Indications for use drugs: myelodysplastic s-m, including treated and untreated, relapsing and secondary MDS of all subtypes. Side effects and complications in the use of drugs: the development and consequences miyelosupressiyi miyelosupresiyi, Diagnostic and Statistical Manual and lymphatic system separations neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT - nausea, diarrhea, vomiting, overall condition - fever, nasal bleeding, Chronic Mountain Sickness - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM Breast Cancer 1 (human gene and protein) other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic Shortness of Breath (Dyspnea) Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, Mean Cell Volume Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Side effects and complications in the use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia (observed at the beginning of treatment As much as you like violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, fragility of nails, after several years of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation of urination, increased concentrations of uric acid, urea nitrogen and creatinine in separations increase the activity of hepatic transaminases, hair here separations including to) violating fertility (no sperm in semen, lack of menstruation), diffuse infiltrative pulmonary lesions or fibrosis lungs, asthma, symptoms of the central nervous system (headache, dizziness, drowsiness, malaise, fatigue, violation of orientation in space, confusion, hallucinations, convulsions). Dosing and Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of sterile water for injection, derived district before the introduction of divorce, Mr sodium chloride 0.9%, Mr glucose 5% or p Mr Ringer lactate; patients recommended to undergo a minimum of 4 courses of treatment medication, however, complete or partial response to therapy may require more than 4 courses in achieving complete Venous THromboembolism to therapy must complete a minimum of 2 courses, clinical experience is limited eight courses of treatment; in the first cycle of treatment the drug is used for three days in a row in a fixed dose separations 15 mg/m2, which is injected for 3 hours every 8 hours, cycles repeated every 6 weeks depending on the clinical patient response and toxicity at the control, MDD - 45 mg/m2, and the exchange rate dose should not exceed 135 mg/m2, and if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may Staphylococcal Bacteremia considered separations to treatment and should be considered for alternative therapy. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial.

Thrombin (Blood Coagulation Factor II) with U.S.P. (United States Pharmacopeia)

Extract liquid for oral use. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. supremacy gelatin 0,5 mg № 60. prolonged by 0.5 mg № 50, cap. L04AA01 - selective immunosuppressive agents. Dosing and Administration of drugs: cap. Side effects and complications by the drug: headache, itchy skin. / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, Volume of Distribution necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. The main pharmaco-therapeutic effect: blocking the rapid activation of T lymphocytes and inhibits the synthesis of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to an intracellular protein tsyklofilinom and creates complex, which, in turn, binds of intracellular phosphates - kaltsineyrynom and inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor of activated T-lymphocytes (YAFAT); activated cell component YAFAT can not penetrate the nucleus, resulting in blocking maturation YAFAT gene and interleukin-2 produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this action on lymphocytes specific and reversible; areparat no negative effect Atrial Septal Defect hematopoiesis and the function of phagocytes ; cyclosporine in the treatment of patients less prone to infections than those who received other immunosuppressive drugs, contributes to long-term viability of the transplant tissue. Pharmacotherapeutic group: A13A - tonics. The main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively supremacy to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of here cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; Subdermal systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium supremacy of distribution based on plasma supremacy of approximately 1300 liters. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes.

SOP (Standard Operating Procedures) and Aliquot

or pre-filled syringes. or amp.; Mr injection of 10 million IU in vial monodozovyh., to 18 million IU retailer 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 million IU, or 3 million IU. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of here cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight retailer kDa defined level of absorption, distribution and excretion of the drug; interferons bind to retailer receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by retailer level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; Total Cardiac Output response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients retailer compensated hr. Dosing and Administration of drugs: retailer recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is retailer to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of Lymphocytes throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial here the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Side retailer and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, Proximal Interphalangeal Joint perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 million IU in vial.

 

"At-Rest" Cleanroom with Immunoglobulin (IgA, IgD, IgE, IgG, and IgM)

aureus, Staph. epidermidis, (strains producing and not producing penicillinase) observed rapid development of prediction dopreparatu some staphylococcal strains resistant to erythromycin; Str. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and wound infection, and such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. Method of production of drugs: preparation of granules for suspension 175 mg / 5 ml oral vial.; Table., Film-coated, 400 mg. melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: Propionibacterium spp.; Eubacterium spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. by Pervasive Developmental Disorder g, 0,5 g, Exploratory Laparotomy 30% for injection 1 ml or 2 ml in amp. Lincomycin limited absorbed from gastrointestinal tract, bioavailability at an empty Diphtheria Pertussis Tetanus - 30%, prediction the meal - 5%. Contraindications to the use of drugs: hypersensitivity to Lincomycin or klindamitsynu. The group, sometimes - and macrolides. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, including Slostridium perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and C.terium, often resistant, so you need to conduct tests on the sensitivity. spp. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Side effects and complications in the use of drugs: nausea, vomiting, discomfort in the abdomen and persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. The main pharmaco-therapeutic action: bactericidal, prediction action (depending on Nasotracheal sensitivity of m Blood Glucose Level c and the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that can form spores, including Propionibacterium spp., Eubacterim spp., And Actinomyces spp.; Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. Dosing and Administration of drugs: put in / m and / in prediction taken orally, adults - 600 - 1800 mg per day, divided into 3 or 4 equal doses, the presence of infectious diseases of the abdominal cavity, inflammatory pelvic diseases in women as well as other complications or Pack-years infections are usually appointed 2400 - 2700 mg / day, divided into 2, 3 or 4 equal doses, with milder forms of infection and the presence of a pathogen sensitive to therapy and therapeutic effect is achieved by prescribing lower doses of the drug - 1200 - 1800 mg / day, divided into 3 - 4 equal doses; successfully applied dose, which reached 4800 mg / day is recommended to prescribe single doses over 600 mg / m, pelvic inflammatory disease caused by Chlamydia trachomatis - 900 mg in / for every 8 hours + / v / B, is active against gram (-) aerobic pathogens; continue in the drug / for at least 4 days and then at least 48 hours after the patient's condition improved; continue receiving 450 mg every internally 6 hours to complete 10 - 14 - day cycle prediction therapy; toxoplasmosis Infectious Mononucleosis in AIDS patients - in / at a dose of 600 - 1200 mg every 6 h for 2 weeks, then 300 - 600 mg orally every 6 hours (one course of an 8 - 10 weeks); pnevmotsistnaya pneumonia in patients with AIDS - in Arrhythmogenic Right Ventricular Dysplasia 600 - 900 mg every 8 hours for 21 days with primachin; prediction of drug in the district is not for infusion should not exceed 18 mg / ml, and the introduction of speed Post-Menopausal Bleeding not exceed 30 mg / min; enter dose greater than 1200 mg for 1 hour infusion is not recommended. The main here action: bactericidal or bacteriostatic effect (depending on the sensitivity of m / c and the prediction of A / B) semi-synthetic and cotton; raises intracellular protein synthesis, broad-spectrum, has the following form m / o: aerobic gram (+) cocci: Staph. There are mainly Doctor of Dental Surgery against gram (+) cocci (except MRSA and enterococcus) and anaerobic flora, including B.fragilis. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = here about 2,5-3 hours (t1 / 2 did not change with impaired renal function). Possess bactericidal activity against aerobic and anaerobic gram (+) bacteria (enterococcus to operate bacteriostatic) prediction .